Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 3:26 AM
Ignite Modification Date: 2025-12-26 @ 2:06 AM
NCT ID: NCT01107405
Description: None
Frequency Threshold: 5
Time Frame: 14 days
Study: NCT01107405
Study Brief: Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Loteprednol Etabonate Base (QD) Loteprednol etabonate ophthalmic base dosed once/day. None None 0 21 0 21 View
Loteprednol Etabonate Base (BID) Loteprednol etabonate ophthalmic base dosed two times/day None None 0 20 4 20 View
Loteprednol Etabonate Base (QID) Loteprednol etabonate ophthalmic base dosed four times/day. None None 0 20 5 20 View
Loteprednol Etabonate Suspension (QID) Loteprednol etabonate ophthalmic suspension dosed four times/day None None 0 20 1 20 View
Vehicle of Loteprednol Etabonate Vehicle of loteprednol etabonate, dosed either QD, BID, or QID None None 0 20 6 20 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Eye irritation SYSTEMATIC_ASSESSMENT Eye disorders MedDRA (12.1) View
Eye pruritis SYSTEMATIC_ASSESSMENT Eye disorders MedDRA (12.1) View
Blurred vision SYSTEMATIC_ASSESSMENT Eye disorders MedDRA (12.1) View
Neck pain SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (12.1) View
Oropharyngial pain SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (12.1) View
Eye pain SYSTEMATIC_ASSESSMENT Eye disorders MedDRA (12.1) View
Back pain SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (12.1) View
Myalgia SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (12.1) View
Temporomandibular joint syndrome SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (12.1) View
Post nasal drip SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (12.1) View
Muscle strain SYSTEMATIC_ASSESSMENT Injury, poisoning and procedural complications MedDRA (12.1) View
Road traffic accident SYSTEMATIC_ASSESSMENT Injury, poisoning and procedural complications MedDRA (12.1) View
Ear pain SYSTEMATIC_ASSESSMENT Ear and labyrinth disorders MedDRA (12.1) View
Blood oestrogen decreased SYSTEMATIC_ASSESSMENT Investigations MedDRA (12.1) View
Dysgeusia SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (12.1) View